Asunto(s)
Síndrome de Inmunodeficiencia Adquirida , Tumor de Buschke-Lowenstein , Condiloma Acuminado , Infecciones por VIH , Láseres de Gas , Vacunas contra Papillomavirus , Acitretina , Condiloma Acuminado/diagnóstico , Condiloma Acuminado/terapia , Femenino , Infecciones por VIH/complicaciones , Infecciones por VIH/diagnóstico , Humanos , Láseres de Gas/efectos adversos , VulvaRESUMEN
We retrospectively reviewed the clinical features, management and outcomes of patients diagnosed with basal cell carcinoma (BCC) of the vulva at the Gynaecological Cancer Centre, KK Women's and Children's Hospital, Singapore, between 1 January 2000 and 28 February 2014. Patients with vulvar BCC were identified from the cancer registry, and their medical records reviewed and analysed. A total of 11 patients with vulvar BCC were identified. Mean age at diagnosis was 63 (range 30-85) years. Ethnically, ten patients were Chinese and one was Malay. Average time from onset of symptoms to diagnosis was 13.8 (range 2-60) months. The most common presenting symptoms were lump and pruritus. All patients were managed surgically. Recurrence was noted in only one patient. Vulvar BCC, although rare, has an excellent prognosis when managed appropriately. Histological diagnosis of all persistent papules, plaques and pigmented lesions is important for early diagnosis.
Asunto(s)
Carcinoma Basocelular/diagnóstico , Carcinoma Basocelular/terapia , Neoplasias de la Vulva/diagnóstico , Neoplasias de la Vulva/terapia , Adulto , Anciano , Anciano de 80 o más Años , Biopsia , Carcinoma Basocelular/etnología , Femenino , Humanos , Persona de Mediana Edad , Pronóstico , Prurito/complicaciones , Sistema de Registros , Estudios Retrospectivos , Singapur/epidemiología , Centros de Atención Terciaria , Resultado del Tratamiento , Neoplasias de la Vulva/etnologíaRESUMEN
OBJECTIVE: The use of adjuvant radiotherapy for early stage node negative patients varies for different institutions. The recognized factors such as deep stromal invasion, lymph vascular space invasion, and size of tumor are the most common factors cited for adjuvant radiotherapy. Studies done have shown that this increases local control but may increase chronic toxicity rates. We report on our use of the GOG score to tailor our treatment decisions. METHODS: A review of all patients staged IB-IIA who underwent Type 3 Radical Hysterectomy and pelvic lymph node dissection (RH) from 1997 to 2007. The GOG score proposed by Delgado et al. was applied, and patients were stratified into 3 groups; <40: no adjuvant treatment, 40-120: Small Field RT (SmRT), and >120: Standard Field RT (StRT) RESULTS: A total of 126 patients matched these criteria. Sixty one patients underwent either SmRT or StRT. There were only 2 known relapses and one death due to inter current illness. The median follow up was 57 months and the 5 year Disease Free Survival was 98.2%. There were no documented Grade 3 or 4 chronic toxicities. There were significantly less (p=0.025) patients with lower limb lymphedema in the SmRT group compared to StRT. CONCLUSION: Our study confirms the utility of the GOG score to tailor radiotherapy for this cohort of patients. This has been proven to be high in efficacy and low in morbidity.